Online Program Home
My Program
All Times EDT
Legend:
* = applied session ! = JSM meeting theme
Activity Details
|
|
|
|
342 *
|
Wed, 8/5/2020,
10:00 AM -
2:00 PM
|
Virtual
|
|
Clinical Trial Design: Statistical Methods and Applications in Oncology — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Davis Gates, Merck
|
|
|
Application of Modulated Markov Models and Modulated Renewal Process for Analyzing Clinical Trial Data with Non-Proportional Hazard
Rianka Bhattacharya, Abbvie Inc.
|
|
|
A Generalized Framework of Optimal Two-Stage Designs for Exploratory Basket Trials
Fang Liu, Merck & Co., Inc; Xiaoqiang Wu, Florida State University; Iris Wu, Merck; Heng Zhou, Merck; Cong Chen, Merck and Company, Inc.
|
|
|
A Dose Escalation Design Considering Different Toxicity Onset Time Frames Using a Bayesian Piecewise Proportional Hazard Model
Hongjie Zhu, Beigene
|
|
|
The Optimal Randomization Ratio in Time-to-Event Trials Is Not 1:1
Godwin Yung, Genentech/Roche; Yi Liu, Nektar Therapeutics
|
|
|
Two-Stage Design for Single-Arm Phase II Cancer Clinical Trials with Two Alternative Primary Endpoints
Hui Gu, Boehringer Ingelheim; Yong Lin, Rutgers School of Public Health; Weichung Joe Shih, Rutgers School of Public Health; Yaqun Wang, Rutgers, School of Public Health, Dept. of Biostatistics; Kejian Liu, Sanofi
|
|
